I-Mab
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About IMAB
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Find out what a historical investment in I-Mab would be worth today using our IMAB stock calculator.
$69.46M
-
0.00%
36.89K
$0.89
$0.82
$0.85
$2.00
$0.60
Ready to start your investing journey with Stake?
Open an accountIMAB FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in IMAB
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in IMAB
on Stake
Buy IMAB from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of IMAB from only US$10 with fractional shares
